Tyrosine kinase inhibitor resistance in cancer: Role of ABC multidrug transporters

Drug Resistance Updates

Volumn 8, Issue 1-2, 2005, Pages 15-26

  Özvegy Laczka, Csilla ^a   Cserepes, Judit ^a,b   Elkind, N Barry ^a   Sarkadi, Balázs ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b INSTITUTE OF ENZYMOLOGY   (Hungary)

Author keywords

ABCG2; Cancer drug resistance; Multidrug transporter; Polymorphic variants; Xenobiotic transport

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; AAL 993; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; AZD 0530; BREAST CANCER RESISTANCE PROTEIN; CANERTINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EKI 785; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ESTRONE SULFATE; ETOPOSIDE; FLAVOPIRIDOL; GEFITINIB; GEMCITABINE; GLYCOPROTEIN P; IMATINIB; IRINOTECAN; KO 143; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PELITINIB; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SUNITINIB; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB; VINCRISTINE;

ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOTOXICITY; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ESOPHAGUS CARCINOMA; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; THROMBOEMBOLISM; TUMOR CELL; TUMOR RESISTANCE;

EID: 20444393495     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2005.02.002     Document Type: Article

References (120)

1. B.L. Abbott, A.M. Colapietro, Y. Barnes, F. Marini, M. Andreeff, and B.P. Sorrentino Low levels of ABCG2 expression in adult AML blast samples Blood 100 2002 4594 4601
2. J.D. Allen, and A.H. Schinkel Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2) Mol. Cancer Ther. 1 2002 427 434
3. N.G. Anderson, T. Ahmad, K. Chan, R. Dobson, and N.J. Bundred ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression Int. J. Cancer 94 2001 774 782
4. J. Anido, P. Matar, J. Albanell, M. Guzman, F. Rojo, J. Arribas, S. Averbuch, and J. Baselga ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells Clin. Cancer Res. 9 2003 1274 1283
5. C.L. Arteaga Selecting the right patient for tumor therapy Nat. Med. 10 2004 577 578
6. C.L. Arteaga, and D.H. Johnson Tyrosine kinase inhibitors-ZD1839 (Iressa) Curr. Opin. Oncol. 13 2001 491 498
7. G. Backstrom, J. Taipalensuu, H. Melhus, H. Brandstrom, A.C. Svensson, P. Artursson, and A. Kindmark Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population Eur. J. Pharm. Sci. 18 2003 359 364
8. A.J. Barker, K.H. Gibson, W. Grundy, A.A. Godfrey, J.J. Barlow, M.P. Healy, J.R. Woodburn, S.E. Ashton, B.J. Curry, L. Scarlett, L. Henthorn, and L. Richards Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg. Med. Chem. Lett. 11 2001 1911 1914
9. J. Bart, H. Hollema, H.J. Groen, E.G. de Vries, N.H. Hendrikse, D.T. Sleijfer, T.D. Wegman, W. Vaalburg, and W.T. van der Graaf The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours Eur. J. Cancer 40 2004 2064 2070
10. S.E. Bates Solving the problem of multidrug resistance: ABC transporters in clinical oncology I.B. Holland S.P. Cole K. Kuchler C.F. Higgins ABC Proteins from Bacteria to Man 2003 Academic Press London 359 392
11. G. Blackledge, and S. Averbuch Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors Br. J. Cancer 90 2004 566 572
12. P. Bonomi Clinical studies with non-Iressa EGFR tyrosine kinase inhibitors Lung Cancer 41 Suppl. 1 2003 S43 S48
13. M. Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, C. Takimoto, R. Robey, Y. Pommier, T. Fojo, and S.E. Bates Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells Cancer Res. 59 1999 5938 5946
14. H. Burger, H. van Tol, A.W. Boersma, M. Brok, E.A. Wiemer, G. Stoter, and K. Nooter Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump Blood 104 2004 2940 2942
15. M. Campiglio, A. Locatelli, C. Olgiati, N. Normanno, G. Somenzi, L. Vigano, M. Fumagalli, S. Menard, and L. Gianni Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level J. Cell. Physiol. 198 2004 259 268
16. L. Candeil, I. Gourdier, D. Peyron, N. Vezzio, V. Copois, F. Bibeau, B. Orsetti, G.L. Scheffer, M. Ychou, Q.A. Khan, Y. Pommier, B. Pau, P. Martineau, and M. Del Rio ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases Int. J. Cancer 109 2004 848 854
17. T. Chano, K. Mori, K. Scotlandi, S. Benini, C. Lapucci, M.C. Manara, M. Serra, P. Picci, H. Okabe, and N. Baldini Differentially expressed genes in multidrug resistant variants of U-2 OS human osteosarcoma cells Oncol. Rep. 11 2004 1257 1263
18. J.S. Chen, K. Lan, and M.C. Hung Strategies to target HER2/neu overexpression for cancer therapy Drug Resist. Update 6 2003 129 136
19. F. Ciardiello, and G. Tortora Anti-epidermal growth factor receptor drugs in cancer therapy Expert. Opin. Investig. Drugs 11 2002 755 768
20. F. Ciardiello, and G. Tortora Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs Eur. J. Cancer 39 2003 1348 1354
21. M.H. Cohen, G.A. Williams, R. Sridhara, G. Chen, W.D. McGuinn Jr., D. Morse, S. Abraham, A. Rahman, C. Liang, R. Lostritto, A. Baird, and R. Pazdur United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets Clin. Cancer Res. 10 2004 1212 1218
22. H.C. Cooray, C.G. Blackmore, L. Maskell, and M.A. Barrand Localisation of breast cancer resistance protein in microvessel endothelium of human brain Neuroreport 13 2002 2059 2063
23. Y. Dai, M. Rahmani, S.J. Corey, P. Dent, and S. Grant A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2 J. Biol. Chem. 279 2004 34227 34239
24. J.E. Dancey, and B. Freidlin Targeting epidermal growth factor receptor - are we missing the mark? Lancet 362 2003 62 64
25. H. Daub, K. Specht, and A. Ullrich Strategies to overcome resistance to targeted protein kinase inhibitors Nat. Rev. Drug Discov. 3 2004 1001 1010
26. F.A. de Jong, S. Marsh, R.H. Mathijssen, C. King, J. Verweij, A. Sparreboom, and H.L. McLeod ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition Clin. Cancer Res. 10 2004 5889 5894
27. C.M. de Silva, and R. Reid Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib Pathol. Oncol. Res. 9 2003 13 19
28. R.G. Deeley, and S.P. Cole Multidrug Resistance Protein 1 (ABCC1) I.B. Holland S.P. Cole K. Kuchler C.F. Higgins ABC Proteins from Bacteria to Man 2003 Academic Press London 393 422
29. M.W. Deininger Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia J. Cancer Res. Clin. Oncol. 130 2004 59 72
30. M.W. Deininger, and B.J. Druker Specific targeted therapy of chronic myelogenous leukemia with imatinib Pharmacol. Rev. 55 2003 401 423
31. C.G. Dietrich, A. Geier, and R.P. Oude Elferink ABC of oral bioavailability: transporters as gatekeepers in the gut Gut 52 2003 1788 1795
32. L.A. Doyle, and D.D. Ross Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 2003 7340 7358
33. J. Drevs PTK/ZK (Novartis) IDrugs 6 2003 787 794
34. A. Duensing, M.C. Heinrich, C.D. Fletcher, and J.A. Fletcher Biology of gastrointestinal stromal tumors: KIT mutations and beyond Cancer Invest. 22 2004 106 116
35. Elkind, N., Szentpetery, Z., Apati, A., Ozvegy-Laczka, C., Varady, G., Ujhelly, O., Szabo, K., Homolya, L., Varadi, A., Buday, L., Keri, G., Nemet, K., Sarkadi, B., 2005. The multidrug transporter ABCG2 prevents tumor cell death induced by the EGF receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 65.
36. C. Erlichman, S.A. Boerner, C.G. Hallgren, R. Spieker, X.Y. Wang, C.D. James, G.L. Scheffer, M. Maliepaard, D.D. Ross, K.C. Bible, and S.H. Kaufmann The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux Cancer Res. 61 2001 739 748
37. P.T. Ferrao, M.J. Frost, S.P. Siah, and L.K. Ashman Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro Blood 102 2003 4499 4503
38. J.A. Fletcher Role of KIT and platelet-derived growth factor receptors as oncoproteins Semin. Oncol. 31 2004 4 11
39. R.E. Friedrich, C. Punke, and A. Reymann Expression of multi-drug resistance genes (mdr1, mrp1, bcrp) in primary oral squamous cell carcinoma In Vivo 18 2004 133 147
40. S. Galimberti, F. Guerrini, G.A. Palumbo, U. Consoli, R. Fazzi, F. Morabito, V. Santini, and M. Petrini Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients Leukoc. Res. 28 2004 367 372
41. C. Gambacorti-Passerini, M. Zucchetti, D. Russo, R. Frapolli, M. Verga, S. Bungaro, L. Tornaghi, F. Rossi, P. Pioltelli, E. Pogliani, D. Alberti, G. Corneo, and M. D'Incalci Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients Clin. Cancer Res. 9 2003 625 632
42. G. Giaccone The role of gefitinib in lung cancer treatment Clin. Cancer Res. 10 2004 4233s 4237s
43. M.M. Gottesman, I. Pastan, and S.V. Ambudkar P-glycoprotein and multidrug resistance Curr. Opin. Genet. Dev. 6 1996 610 617
44. J.R. Grandis, and J.C. Sok Signaling through the epidermal growth factor receptor during the development of malignancy Pharmacol. Ther. 102 2004 37 46
45. A. Gschwind, O.M. Fischer, and A. Ullrich The discovery of receptor tyrosine kinases: targets for cancer therapy Nat. Rev. Cancer 4 2004 361 370
46. T. Hegedus, L. Orfi, A. Seprodi, A. Varadi, B. Sarkadi, and G. Keri Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1 Biochim. Biophys. Acta 1587 2002 318 325
47. R.S. Herbst Review of epidermal growth factor receptor biology Int. J. Radiat. Oncol. Biol. Phys. 59 2004 21 26
48. R.S. Herbst, M. Fukuoka, and J. Baselga Gefitinib - a novel targeted approach to treating cancer Nat. Rev. Cancer 4 2004 956 965
49. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, V. Miller, C. Manegold, G. Scagliotti, R. Rosell, I. Oliff, J.A. Reeves, M.K. Wolf, A.D. Krebs, S.D. Averbuch, J.S. Ochs, J. Grous, A. Fandi, and D.H. Johnson Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J. Clin. Oncol. 22 2004 785 794
50. C.F. Higgins ABC transporters: from microorganisms to man Annu. Rev. Cell Biol. 8 1992 67 113
51. C. Hirschmann-Jax, A.E. Foster, G.G. Wulf, J.G. Nuchtern, T.W. Jax, U. Gobel, M.A. Goodell, and M.K. Brenner A distinct "side population" of cells with high drug efflux capacity in human tumor cells Proc. Natl. Acad. Sci. U.S.A. 101 2004 14228 14233
52. Y. Honjo, K. Morisaki, L.M. Huff, R.W. Robey, J. Hung, M. Dean, and S.E. Bates Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1) Cancer Biol. Ther. 1 2002 696 702
53. P.J. Houghton, G.S. Germain, F.C. Harwood, J.D. Schuetz, C.F. Stewart, E. Buchdunger, and P. Traxler Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro Cancer Res. 64 2004 2333 2337
54. A. Iida, S. Saito, A. Sekine, C. Mishima, Y. Kitamura, K. Kondo, S. Harigae, S. Osawa, and Y. Nakamura Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8 J. Hum. Genet. 47 2002 285 310
55. Y. Imai, M. Nakane, K. Kage, S. Tsukahara, E. Ishikawa, T. Tsuruo, Y. Miki, and Y. Sugimoto C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance Mol. Cancer Ther. 1 2002 611 616
56. A. Inoue, Y. Saijo, M. Maemondo, K. Gomi, Y. Tokue, Y. Kimura, M. Ebina, T. Kikuchi, T. Moriya, and T. Nukiwa Severe acute interstitial pneumonia and gefitinib Lancet 361 2003 137 139
57. M. Itoda, Y. Saito, K. Shirao, H. Minami, A. Ohtsu, T. Yoshida, N. Saijo, H. Suzuki, Y. Sugiyama, S. Ozawa, and J. Sawada Eight single nucleotide polymorhisms in ABCG2/BCRP in Japanese cancer patients administered irinotecan Drug Metab. Pharmacokin. 18 2003 212 217
58. M.L. Janmaat, and G. Giaccone Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors Oncologist 8 2003 576 586
59. J.W. Jonker, M. Buitelaar, E. Wagenaar, M.A. Van Der Valk, G.L. Scheffer, R.J. Scheper, T. Plosch, F. Kuipers, R.P. Elferink, H. Rosing, J.H. Beijnen, and A.H. Schinkel The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria Proc. Natl. Acad. Sci. U.S.A. 99 2002 15649 15654
60. J.W. Jonker, J.W. Smit, R.F. Brinkhuis, M. Maliepaard, J.H. Beijnen, J.H. Schellens, and A.H. Schinkel Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan J. Natl. Cancer Inst. 92 2000 1651 1656
61. S. Kawabata, M. Oka, H. Soda, K. Shiozawa, K. Nakatomi, J. Tsurutani, Y. Nakamura, S. Doi, T. Kitazaki, K. Sugahara, Y. Yamada, S. Kamihira, and S. Kohno Expression and functional analyses of breast cancer resistance protein in lung cancer Clin. Cancer Res. 9 2003 3052 3057
62. R. Kim, and T. Toge Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents Surg. Today 34 2004 293 303
63. D. Kobayashi, I. Ieiri, T. Hirota, H. Takane, S. Maegawa, J. Kigawa, H. Suzuki, E. Nanba, M. Oshimura, N. Terakawa, K. Otsubo, K. Mine, and Y. Sugiyama Functional assessment of abcg2 (bcrp) gene polymorphisms to protein expression in human placenta Drug Metab. Dispos. 33 2005 94 101
64. P. Krishnamurthy, D.D. Ross, T. Nakanishi, K. Bailey-Dell, S. Zhou, K.E. Mercer, B. Sarkadi, B.P. Sorrentino, and J.D. Schuetz The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme J. Biol. Chem. 279 2004 24218 24225
65. C.J. Langer Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC Int. J. Radiat. Oncol. Biol. Phys. 58 2004 991 1002
66. G.D. Leonard, T. Fojo, and S.E. Bates The role of ABC transporters in clinical practice Oncologist 8 2003 411 424
67. R. Logrono, D.V. Jones, S. Faruqi, and M.S. Bhutani Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST) Cancer Biol. Ther. 3 2004 251 258
68. C. Luo, and P. Laaja Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs Drug Discov. Today 9 2004 268 275
69. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
70. F.X. Mahon, F. Belloc, V. Lagarde, C. Chollet, F. Moreau-Gaudry, J. Reiffers, J.M. Goldman, and J.V. Melo MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models Blood 101 2003 2368 2373
71. F.X. Mahon, M.W. Deininger, B. Schultheis, J. Chabrol, J. Reiffers, J.M. Goldman, and J.V. Melo Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood 96 2000 1070 1079
72. M. Maliepaard, G.L. Scheffer, I.F. Faneyte, M.A. van Gastelen, A.C. Pijnenborg, A.H. Schinkel, M.J. van De Vijver, R.J. Scheper, and J.H. Schellens Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues Cancer Res. 61 2001 3458 3464
73. P.W. Manley, G. Bold, J. Bruggen, G. Fendrich, P. Furet, J. Mestan, C. Schnell, B. Stolz, T. Meyer, B. Meyhack, W. Stark, A. Strauss, and J. Wood Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis Biochim. Biophys. Acta 1697 2004 17 27
74. G. McArthur Molecularly targeted treatment for dermatofibrosarcoma protuberans Semin. Oncol. 31 2004 30 36
75. J.V. Melo, T.P. Hughes, and J.F. Apperley Chronic myeloid leukemia Hematology (Am. Soc. Hematol. Educ. Program) 2003 132 152
76. K. Miyake, L. Mickley, T. Litman, Z. Zhan, R. Robey, B. Cristensen, M. Brangi, L. Greenberger, M. Dean, T. Fojo, and S.E. Bates Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes Cancer Res. 59 1999 8 13
77. S. Mizuarai, N. Aozasa, and H. Kotani Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2 Int. J. Cancer 109 2004 238 246
78. N. Mizuno, M. Suzuki, H. Kusuhara, H. Suzuki, K. Takeuchi, T. Niwa, J.W. Jonker, and Y. Sugiyama Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2- methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice Drug Metab. Dispos. 32 2004 898 901
79. Morisaki, K., Robey, R., Ozvegy-Laczka, C., Honjo, Y., Polgar, O., Steadman, K., Sarkadi, B., Bates, S., in press. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol.
80. M. Mukai, X.F. Che, T. Furukawa, T. Sumizawa, S. Aoki, X.Q. Ren, M. Haraguchi, Y. Sugimoto, M. Kobayashi, H. Takamatsu, and S. Akiyama Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells Cancer Sci. 94 2003 557 563
81. T. Nakanishi, J.E. Karp, M. Tan, L.A. Doyle, T. Peters, W. Yang, D. Wei, and D.D. Ross Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients Clin. Cancer Res. 9 2003 3320 3328
82. V. Nardi, M. Azam, and G.Q. Daley Mechanisms and implications of imatinib resistance mutations in BCR-ABL Curr. Opin. Hematol. 11 2004 35 43
83. R. Nimmanapalli, and K. Bhalla Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias Curr. Opin. Oncol. 14 2002 616 620
84. M.E. Noble, J.A. Endicott, and L.N. Johnson Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800 1805
85. M.E. O'Dwyer, M.J. Mauro, and B.J. Druker STI571 as a targeted therapy for CML Cancer Invest. 21 2003 429 438
86. A.M. O'Farrell, T.J. Abrams, H.A. Yuen, T.J. Ngai, S.G. Louie, K.W. Yee, L.M. Wong, W. Hong, L.B. Lee, A. Town, B.D. Smolich, W.C. Manning, L.J. Murray, M.C. Heinrich, and J.M. Cherrington SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 2003 3597 3605
87. C. Ozvegy-Laczka, T. Hegedus, G. Varady, O. Ujhelly, J.D. Schuetz, A. Varadi, G. Keri, L. Orfi, K. Nemet, and B. Sarkadi High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter Mol. Pharmacol. 65 2004 1485 1495
88. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
89. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, and H. Varmus EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U.S.A. 101 2004 13306 13311
90. H.S. Parra, R. Cavina, F. Latteri, P.A. Zucali, E. Campagnoli, E. Morenghi, G.C. Grimaldi, M. Roncalli, and A. Santoro Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer Br. J. Cancer 91 2004 208 212
91. R.W. Robey, W.Y. Medina-Perez, K. Nishiyama, T. Lahusen, K. Miyake, T. Litman, A.M. Senderowicz, D.D. Ross, and S.E. Bates Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells Clin. Cancer Res. 7 2001 145 152
92. D.R. Robinson, Y.M. Wu, and S.F. Lin The protein tyrosine kinase family of the human genome Oncogene 19 2000 5548 5557
93. R. Roskoski Jr. STI-571: an anticancer protein-tyrosine kinase inhibitor Biochem. Biophys. Res. Commun. 309 2003 709 717
94. E.K. Rowinsky Signal events: cell signal transduction and its inhibition in cancer Oncologist 8 Suppl. 3 2003 5 17
95. D.G. Savage, and K.H. Antman Imatinib mesylate - a new oral targeted therapy N. Engl. J. Med. 346 2002 683 693
96. A. Sawaki, and K. Yamao Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors - a review Cancer Chemother. Pharmacol. 54 Suppl. 1 2004 S44 S49
97. N.P. Shah, and C.L. Sawyers Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias Oncogene 22 2003 7389 7395
98. Q.B. She, D. Solit, A. Basso, and M.M. Moasser Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling Clin. Cancer Res. 9 2003 4340 4346
99. T. Sjoblom, A. Shimizu, K.P. O'Brien, K. Pietras, P. Dal Cin, E. Buchdunger, J.P. Dumanski, A. Ostman, and C.H. Heldin Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis Cancer Res. 61 2001 5778 5783
100. B.D. Smith, M. Levis, M. Beran, F. Giles, H. Kantarjian, K. Berg, K.M. Murphy, T. Dauses, J. Allebach, and D. Small Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Blood 103 2004 3669 3676
101. A. Sparreboom, R. Danesi, Y. Ando, J. Chan, and W.D. Figg Pharmacogenomics of ABC transporters and its role in cancer chemotherapy Drug Resist. Update 6 2003 71 84
102. L.S. Steelman, S.C. Pohnert, J.G. Shelton, R.A. Franklin, F.E. Bertrand, and J.A. McCubrey JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis Leukemia 18 2004 189 218
103. C.F. Stewart, M. Leggas, J.D. Schuetz, J.C. Panetta, P.J. Cheshire, J. Peterson, N. Daw, J.J. Jenkins III, R. Gilbertson, G.S. Germain, F.C. Harwood, and P.J. Houghton Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice Cancer Res. 64 2004 7491 7499
104. R.M. Stone, D.J. Deangelo, V. Klimek, I. Galinsky, E. Estey, S.D. Nimer, W. Grandin, D. Lebwohl, Y. Wang, P. Cohen, E.A. Fox, D. Neuberg, J. Clark, D.G. Gilliland, and J.D. Griffin Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Blood 105 2005 54 60
105. A. Suvannasankha, H. Minderman, K.L. O'Loughlin, T. Nakanishi, W.R. Greco, D.D. Ross, and M.R. Baer Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function Leukemia 18 2004 1252 1257
106. J. Thomas, L. Wang, R.E. Clark, and M. Pirmohamed Active transport of imatinib into and out of cells: implications for drug resistance Blood 104 2004 3739 3745
107. A.Y. Tsygankov, and S.K. Shore Src: regulation, role in human carcinogenesis and pharmacological inhibitors Curr. Pharm. Des. 10 2004 1745 1756
108. K. Ueda, M. Matsuo, K. Tanabe, K. Morita, N. Kioka, and T. Amachi Comparative aspects of the function and mechanism of SUR1 and MDR1 proteins Biochim. Biophys. Acta 1461 1999 305 313
109. M.M. van den Heuvel-Eibrink, E.A. Wiemer, A. Prins, J.P. Meijerink, P.J. Vossebeld, B. van der Holt, R. Pieters, and P. Sonneveld Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) Leukemia 16 2002 833 839
110. D.M. van der Kolk, E. Vellenga, G.L. Scheffer, M. Muller, S.E. Bates, R.J. Scheper, and E.G. de Vries Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia Blood 99 2002 3763 3770
111. M.A. van der Pol, H.J. Broxterman, J.M. Pater, N. Feller, M. van der Maas, G.W. Weijers, G.L. Scheffer, J.D. Allen, R.J. Scheper, A. van Loevezijn, G.J. Ossenkoppele, and G.J. Schuurhuis Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia Haematologica 88 2003 134 147
112. A.E. van Herwaarden, J.W. Jonker, E. Wagenaar, R.F. Brinkhuis, J.H. Schellens, J.H. Beijnen, and A.H. Schinkel The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine Cancer Res. 63 2003 6447 6452
113. H.M. Verheul, and H.M. Pinedo Vascular endothelial growth factor and its inhibitors Drugs Today (Barc) 39 Suppl. C 2003 81 93
114. G. Vlahovic, and J. Crawford Activation of tyrosine kinases in cancer Oncologist 8 2003 531 538
115. E.L. Volk, K. Rohde, M. Rhee, J.J. McGuire, L.A. Doyle, D.D. Ross, and E. Schneider Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux Cancer Res. 60 2000 3514 3521
116. M. Warmuth, R. Damoiseaux, Y. Liu, D. Fabbro, and N. Gray SRC family kinases: potential targets for the treatment of human cancer and leukemia Curr. Pharm. Des. 9 2003 2043 2059
117. E. Weisberg, and J.D. Griffin Resistance to imatinib (Glivec): update on clinical mechanisms Drug Resist. Update 6 2003 231 238
118. K. Yanase, S. Tsukahara, S. Asada, E. Ishikawa, Y. Imai, and Y. Sugimoto Gefitinib reverses breast cancer resistance protein-mediated drug resistance Mol. Cancer Ther. 3 2004 1119 1125
119. C.P. Zamber, J.K. Lamba, K. Yasuda, J. Farnum, K. Thummel, J.D. Schuetz, and E.G. Schuetz Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine Pharmacogenetics 13 2003 19 28
120. S. Zhou, J.D. Schuetz, K.D. Bunting, A.M. Colapietro, J. Sampath, J.J. Morris, I. Lagutina, G.C. Grosveld, M. Osawa, H. Nakauchi, and B.P. Sorrentino The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype Nat. Med. 7 2001 1028 1034